Based on the above research results, we created radar charts to qualitatively compare the capabilities of patient-derived primary and recurrent glioma stem cells as follows: the inhibitory efficiency of TRAF7 inhibition and CCNU treatment, tumor sphere size, CD133 expression levels, and migration capacity. This evidence concerns the gene PROM1 and glioma.